BACKGROUND: Preliminary data indicate that tyrosine kinase inhibitors (TKIs) function through rearranged during transfection (RET) in breast cancer. However, TKIs are not specific and can block several receptor tyrosine kinases (RTKs). This study used cell lines and primary breast cancer specimens to determine factors associated with TKI response. METHODS: Proliferation was assessed after short interfering RNA knockdown with or without sunitinib in breast cancer cell lines by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Breast cancer tissue and matched normal breast was obtained from 30 women with invasive breast carcinoma. Gene expression was assessed by reverse transcriptase-polymerase chain reaction. Fresh tissue was treated in vitro with sunitinib or control media for 30 min, and response was assessed by phosphorylation-specific western blot. RESULTS: The RTKs including epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFRa/b), and Kit were overexpressed in triple-negative breast tumors relative to HER2- and estrogen receptor-alpha (ERα)-positive tumors and normal breast tissue. Knockdown of EGFR reduced in vitro proliferation in MCF-7 and MDA-MB-231 but not in SKBR-3 or ZR-75-1 breast cancer cells. With the exception of RET, response to sunitinib was independent of RTK expression in all four cell lines. Both ERα-positive and low-EGFR-expressing tumors had an increased in vitro sunitinib response, as determined by alteration of Erk activation. Expression of other RTKs and additional clinical factors were not associated with response. CONCLUSION: Triple-negative breast cancers overexpress RTKs but have decreased in vitro response to the TKI sunitinib. In addition to RET, TKIs that block EGFR may increase the therapeutic efficacy of TKIs in breast cancer.
BACKGROUND: Preliminary data indicate that tyrosine kinase inhibitors (TKIs) function through rearranged during transfection (RET) in breast cancer. However, TKIs are not specific and can block several receptor tyrosine kinases (RTKs). This study used cell lines and primary breast cancer specimens to determine factors associated with TKI response. METHODS: Proliferation was assessed after short interfering RNA knockdown with or without sunitinib in breast cancer cell lines by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide). Breast cancer tissue and matched normal breast was obtained from 30 women with invasive breast carcinoma. Gene expression was assessed by reverse transcriptase-polymerase chain reaction. Fresh tissue was treated in vitro with sunitinib or control media for 30 min, and response was assessed by phosphorylation-specific western blot. RESULTS: The RTKs including epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR1-3), platelet-derived growth factor receptor (PDGFRa/b), and Kit were overexpressed in triple-negative breast tumors relative to HER2- and estrogen receptor-alpha (ERα)-positive tumors and normal breast tissue. Knockdown of EGFR reduced in vitro proliferation in MCF-7 and MDA-MB-231 but not in SKBR-3 or ZR-75-1 breast cancer cells. With the exception of RET, response to sunitinib was independent of RTK expression in all four cell lines. Both ERα-positive and low-EGFR-expressing tumors had an increased in vitro sunitinib response, as determined by alteration of Erk activation. Expression of other RTKs and additional clinical factors were not associated with response. CONCLUSION: Triple-negative breast cancers overexpress RTKs but have decreased in vitro response to the TKI sunitinib. In addition to RET, TKIs that block EGFR may increase the therapeutic efficacy of TKIs in breast cancer.
Authors: Oliver Frings; Martin Augsten; Nicholas P Tobin; Joseph Carlson; Janna Paulsson; Cristina Pena; Eleonor Olsson; Srinivas Veerla; Jonas Bergh; Arne Ostman; Erik L L Sonnhammer Journal: Am J Pathol Date: 2013-04-10 Impact factor: 4.307
Authors: Anne Boulay; Madlaina Breuleux; Christine Stephan; Caroline Fux; Cathrin Brisken; Maryse Fiche; Markus Wartmann; Michael Stumm; Heidi A Lane; Nancy E Hynes Journal: Cancer Res Date: 2008-05-15 Impact factor: 12.701
Authors: Katalin Boér; István Láng; Antonio Llombart-Cussac; Inger Andreasson; Guillermo L Vivanco; Nick Sanders; Gillian M Pover; Elizabeth Murray Journal: Invest New Drugs Date: 2010-09-10 Impact factor: 3.850
Authors: Erica L Mayer; Steven J Isakoff; Giannoula Klement; Sean R Downing; Wendy Y Chen; Keri Hannagan; Rebecca Gelman; Eric P Winer; Harold J Burstein Journal: Breast Cancer Res Treat Date: 2012-09-23 Impact factor: 4.872
Authors: A R Cyr; M V Kulak; J M Park; M V Bogachek; P M Spanheimer; G W Woodfield; L S White-Baer; Y Q O'Malley; S L Sugg; A K Olivier; W Zhang; F E Domann; R J Weigel Journal: Oncogene Date: 2014-01-27 Impact factor: 9.867
Authors: James P De Andrade; Jung M Park; Vivian W Gu; George W Woodfield; Mikhail V Kulak; Allison W Lorenzen; Vincent T Wu; Sarah E Van Dorin; Philip M Spanheimer; Ronald J Weigel Journal: Mol Cancer Ther Date: 2016-02-01 Impact factor: 6.261
Authors: Philip M Spanheimer; Amani Bashir; Allison W Lorenzen; Anna C Beck; Junlin Liao; Ingrid M Lizarraga; Lillian M Erdahl; Sonia L Sugg; Mark W Karwal; Ronald J Weigel Journal: Am J Clin Oncol Date: 2021-09-01 Impact factor: 2.787
Authors: Natália Bertoni; Lied M S Pereira; Fábio E Severino; Regina Moura; Winston B Yoshida; Patricia P Reis Journal: BMC Med Genet Date: 2016-01-15 Impact factor: 2.103
Authors: Nan Wu; Jinghua Zhang; Jing Zhao; Kun Mu; Jun Zhang; Zhao Jin; Jinpu Yu; Juntian Liu Journal: Oncol Lett Date: 2018-08-10 Impact factor: 2.967